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Abstract
Objectives: To investigate using quantitative EEG the (1) differences between patients with mild cognitive
impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer’s disease (MCI-AD) and (2) its utility as a potential
biomarker for early differential diagnosis.
Methods: We analyzed eyes-closed, resting-state, high-density EEG data from highly phenotyped participants (39
MCI-LB, 36 MCI-AD, and 31 healthy controls). EEG measures included spectral power in different frequency bands
(delta, theta, pre-alpha, alpha, and beta), theta/alpha ratio, dominant frequency, and dominant frequency variability.
Receiver operating characteristic (ROC) analyses were performed to assess diagnostic accuracy.
Results: There was a shift in power from beta and alpha frequency bands towards slower frequencies in the pre-
alpha and theta range in MCI-LB compared to healthy controls. Additionally, the dominant frequency was slower in
MCI-LB compared to controls. We found significantly increased pre-alpha power, decreased beta power, and slower
dominant frequency in MCI-LB compared to MCI-AD. EEG abnormalities were more apparent in MCI-LB cases with
more diagnostic features. There were no significant differences between MCI-AD and controls. In the ROC analysis
to distinguish MCI-LB from MCI-AD, beta power and dominant frequency showed the highest area under the curve
values of 0.71 and 0.70, respectively. While specificity was high for some measures (up to 0.97 for alpha power and
0.94 for theta/alpha ratio), sensitivity was generally much lower.
Conclusions: Early EEG slowing is a specific feature of MCI-LB compared to MCI-AD. However, there is an overlap
between the two MCI groups which makes it difficult to distinguish between them based on EEG alone.
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Background
The early diagnosis of dementia is becoming increasingly
important as it is likely that potential disease-modifying
treatments will have their greatest effect at this stage.
Additionally, accurate and early differential diagnosis of
dementia subtypes is crucial for correct patient
stratification for clinical trials and research studies and
for optimizing clinical care such as by highlighting the
need to carefully avoid using medication with anticholin-
ergic properties and encouraging active identification of
therapeutic targets such as orthostatic hypotension and
constipation [1].
The intermediate stage between normal aging and de-
mentia in which cognitive decline is present, but inde-
pendence in activities of daily living is still preserved, is
referred to as mild cognitive impairment (MCI) [2, 3].
While much research has focused on MCI patients who
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: julia.schumacher@newcastle.ac.uk
1Translational and Clinical Research Institute, Faculty of Medical Sciences,
Newcastle University, Biomedical Research Building 3rd floor, Campus for
Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK
Full list of author information is available at the end of the article
Schumacher et al. Alzheimer's Research & Therapy           (2020) 12:82 
https://doi.org/10.1186/s13195-020-00650-1
later develop Alzheimer’s disease (AD), MCI in the con-
text of dementia with Lewy bodies (DLB) has only been
characterized more recently with research criteria re-
cently published [4–6]. Differential diagnosis is often im-
peded by a substantial clinical overlap between AD and
DLB, which is especially pronounced in early stages,
highlighting the need for objective biomarkers. In DLB,
dopaminergic brain imaging and myocardial scintigraphy
are indicative biomarkers [7]; these can improve diag-
nostic accuracy at the MCI stage [8] and are included in
the new research criteria for MCI with Lewy bodies
(MCI-LB). EEG has been suggested as a non-invasive al-
ternative, and an abnormal EEG is listed as a supportive
biomarker in the DLB diagnostic criteria [7]. However,
its value for differential diagnosis at the MCI stage is less
certain.
The aims of the present study were therefore to inves-
tigate changes in quantitative EEG measures in a large
cohort of well-characterized patients, all of whom had
biomarker assessments with both dopaminergic and car-
diac MIGB imaging, and to test the utility of EEG as a
biomarker for early differential diagnosis.
The secondary aim was to better understand the rela-
tionship between EEG abnormalities in the MCI-LB
group and the core Lewy body symptoms. We hypothe-
sized that EEG abnormalities would be more severe in
patients with more core symptoms.
Methods
Participants
All participants in this study were over 60 years of age.
Patients with a clinical diagnosis of MCI in memory ser-
vices in the north east of England were screened and
approached for this study if they reported additional
clinical symptoms suggestive of Lewy body disease (e.g.,
mood changes, sleep disturbances, or autonomic symp-
toms) or any core DLB features (visual hallucinations,
cognitive fluctuations, parkinsonism, and REM sleep
behavior disorder). After obtaining written informed
consent, participants underwent a baseline clinical as-
sessment including the Addenbrooke’s Cognitive Exam-
ination–Revised (ACE-R), from which the Mini-Mental
State Examination (MMSE) score was derived; the Uni-
fied Parkinson’s Disease Rating Scale motor sub-score
(UPDRS-III); the Epworth Sleepiness Scale (ESS); and
the Geriatric Depression Scale (GDS). Additionally, the
Instrumental Activities of Daily Living (IADL) Scale, the
Clinician Assessment of Fluctuations (CAF), the Dementia
Cognitive Fluctuations Scale (DCFS), the North-East Vis-
ual Hallucinations Interview (NEVHI), the Neuropsychi-
atric Inventory (NPI), and the Mayo Sleep Questionnaire
(MSQ) were administered to informants, and the Clinical
Dementia Rating (CDR) Scale and the Cumulative Illness
Rating Scale for Geriatrics (CIRS-G) were completed
based on the clinical history and research assessments. In
addition to a detailed clinical assessment, participants had
already undergone dopaminergic imaging with 123I-N-
fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) single-
photon emission computed tomography (FP-CIT SPECT)
and 123iodine-metaiodobenzylguanidine (MIBG) myocar-
dial scintigraphy through their involvement in an ongoing
study investigating the diagnostic accuracy of imaging bio-
markers in MCI, and this information was used to apply
diagnostic criteria (see below).
After the initial baseline visit, participants were followed
annually for up to 3 years with a mean follow-up time of
16.5months (standard deviation = 6.5months). Patients
who were taking dopaminergic medication were assessed
in the “ON” motor state.
Diagnosis
Diagnoses were based on all information available at the
end of the recruitment period (December 2019) includ-
ing any baseline and follow-up visits. MCI diagnoses
were made independently by a consensus panel of three
experienced old-age psychiatrists (AJT, PCD, JPT) in ac-
cordance with NIA-AA criteria [3], i.e., subjective and
objective cognitive impairment with maintained inde-
pendence of function with minimal aids or assistance
and a CDR of 0 or 0.5. Patients with a diagnosis of
dementia were excluded from the study. Furthermore,
patients with possible contributing frontotemporal or
vascular etiologies or with a history of parkinsonism of
more than 1 year prior to the onset of cognitive impair-
ment were excluded. The presence or absence of the
core Lewy body symptoms was rated by the panel utiliz-
ing the rating scales and all information from the clinical
assessments [7]. Findings from the FP-CIT and MIBG
scans were used for diagnosis (see below), but the clin-
ical MCI diagnoses as well as the rating of the presence/
absence of core DLB symptoms were performed blind to
these imaging findings.
A diagnosis of MCI with probable Alzheimer’s disease
(MCI-AD) was given to patients who had no core Lewy
body symptoms, negative FP-CIT and MIBG findings,
and evidence of cognitive decline that was characteristic
of AD, i.e., they met the additional NIA-AA criterion for
“etiology of MCI consistent with AD pathophysiologic
process” [3].
Probable MCI with Lewy bodies (MCI-LB) was diag-
nosed if a patient had two or more core Lewy body
symptoms or one core symptom in addition to a positive
FP-CIT or MIBG scan [6].
Out of 103 MCI participants who were included in the
study, 20 had only one core Lewy body symptom with
negative FP-CIT and MIBG scans or no core symptoms
in addition to a positive FP-CIT or MIBG scan, i.e., they
did not meet the criteria for either MCI-AD or probable
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MCI-LB and were therefore not included in the present
analysis (Fig. 1). Additionally, eight MCI participants did
not have usable EEG data available. This study therefore
included 39 participants who were diagnosed with prob-
able MCI-LB and 36 who were diagnosed with MCI-AD.
Healthy control participants (N = 31) were recruited
from relatives and friends of patients and from a local
research register. Control participants had the same as-
sessment as the patients and had no history of psychi-
atric or neurological illness and no evidence of any
cognitive decline. They also had normal structural MR
imaging. The study was approved by the local ethics
committee, and written informed consent was obtained
from all participants.
EEG acquisition and pre-processing
Resting-state high-density EEG recordings were acquired
from all participants using Waveguard caps (ANT
Neuro, The Netherlands) comprising 128 sintered Ag/
AgCl electrodes that were placed according to the 10-5
system. Participants were seated during the recording
and instructed to remain awake. Electrode impedance
was kept below 5 kΩ, and continuous EEG data were re-
corded at a sampling frequency of 1024 Hz. Three hun-
dred seconds of eyes-closed data were recorded from
each participant. Participants were supervised by the
EEG technician during the recording to monitor adher-
ence to the protocol. The ground electrode was attached
to the right clavicle, and all EEG channels were refer-
enced to Fz during recording.
Pre-processing of eyes-closed EEG data was performed
using the EEGLAB toolbox (version 14) in MATLAB
(R2017a) [9] and was blinded to group membership.
First, EEG data were bandpass-filtered between 0.3 and
54 Hz using a second-order Butterworth filter and split
into non-overlapping epochs of 2 s. Subsequently, EEG
recordings were visually inspected to identify noisy
channels and noisy epochs which were excluded prior to
applying independent component analysis for further
artifact removal. The resulting components were visually
inspected, and components representing muscular, car-
diac, ocular, or electrical (50 Hz line noise) artifacts were
rejected. The previously excluded channels were then re-
placed using spherical spline interpolation, and data
were recomputed against the average reference. For each
participant, the first 45 2-s-long artifact-free epochs were
selected for further analysis.
Frequency analysis
For each 2-s epoch, the power spectral density (PSD)
was estimated using Bartlett’s method in MATLAB
(R2017a) with a frequency resolution of 0.5 Hz and a
Fig. 1 Study flowchart
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Hamming window across the power spectrum from 2 to
30 Hz, for each electrode separately. To compensate for
inter-individual variability in brain neurophysiology,
anatomy, and physical tissue properties, the PSD was
normalized by the total power across the power
spectrum [10].
For each electrode separately, the mean power across all
included epochs was estimated for different standard EEG
frequency bands including delta (2–4Hz), theta (4–5.5
Hz), pre-alpha (5.5–8 Hz), alpha (8–13Hz), and beta (13–
30Hz). Higher frequencies were excluded because these
are particularly affected by muscular artifacts [11]. The
dominant frequency was calculated as the frequency with
the highest power between 4 and 15Hz (averaged across
epochs). Dominant frequency was calculated for all elec-
trodes as well as from occipital electrodes only (PO9,
PO7, POO9h, PO5, O1, PO3, POO3h, OI1h, POz, Oz,
PO4, POO4h, PO6, O2, OI2h, PO8, POO10h, PO10).
Dominant frequency variability was defined as the stand-
ard deviation of dominant frequency across epochs [12].
Statistics
Statistical analyses were performed in SPSS and R
(https://www.r-project.org/). Relative power within the
different frequency bands was compared between the
three groups using a multivariate ANOVA with a
within-subject factor of frequency band and a between-
subject factor of diagnosis, followed by univariate ANO-
VAs and post hoc tests, Bonferroni-corrected for mul-
tiple comparisons. Since relative power was not
normally distributed in all groups, the variables were
log-transformed before applying the ANOVA. Theta/
alpha ratio, dominant frequency, and dominant fre-
quency variability were compared between the groups
using univariate ANOVAs followed by post hoc tests
(Bonferroni-corrected). To account for differences in the
number of male and female participants in the three
groups, sex was included as a covariate in all analyses.
To test the applicability of this analysis to a clinical
setting, the group comparison of relative power within
the different frequency bands was repeated only includ-
ing the 21 electrodes that are part of the 10-20 system
that is routinely used in clinical practice.
Additionally, to test whether EEG changes have a differ-
ent spatial distribution in the different groups, we con-
ducted a supplementary analysis splitting the whole set of
electrodes into four macroscopic regions (frontal, central,
lateral, and posterior) and applying a repeated measures
ANOVA with region as the within-subject factor and
diagnosis as the between-subject factor [10]. If the inter-
action between region and diagnosis was significant, this
was followed up by post hoc univariate ANOVAs.
A receiver operating characteristic (ROC) analysis was
conducted in R to assess the sensitivity and specificity of
the different EEG measures to distinguish between MCI-
AD and MCI-LB patients. The sensitivity/specificity cut-
off was determined using Youden’s index.
To assess the association between the range of Lewy
body symptomatology and EEG abnormalities, we per-
formed an exploratory analysis in which we compared
quantitative EEG measures between MCI-LB patients
who had two core symptoms or one core symptom and
one abnormal biomarker (N = 13) with those patients
who had more than two core symptoms/abnormal bio-
markers (N = 26) using two-sample t tests. Furthermore,
Spearman’s correlations between symptom/biomarker
count (ranging from 2 to 6) and the different EEG mea-
sures were computed in the MCI-LB group.
The association between quantitative EEG measures
and overall cognitive impairment was assessed using
Spearman’s correlations, in the MCI-AD and MCI-LB
groups separately. p values were FDR-corrected for mul-
tiple comparisons.
Additionally, we investigated the association between
EEG characteristics and the core Lewy body symptoms
of visual hallucinations and cognitive fluctuations which
have been shown to be related to EEG abnormalities in
dementia patients [10, 13, 14]. To this end, two-sample t
tests were performed, dichotomizing the MCI-LB group
according to the presence/absence of visual hallucina-
tions and cognitive fluctuations.
Given previous reports of an effect of acetylcholin-
esterase inhibitors on the EEG signal [15, 16], a two-
sample t test was performed in the MCI-LB group to
compare the EEG characteristics between patients who
were taking acetylcholinesterase inhibitors and those pa-
tients not taking these medications.
Results
Demographics
All groups were similar in age (Table 1). The proportion
of male participants was higher in the MCI-LB group
whereas more MCI-AD patients were female. MCI-LB
patients had significantly lower years of education com-
pared to controls, but there was no significant difference
between the two MCI groups in terms of education.
More MCI-LB patients were taking cholinesterase inhib-
itors and Parkinson’s disease medication compared to
MCI-AD patients. The two MCI groups were matched
in terms of overall cognitive impairment. As expected,
the MCI-LB group had more parkinsonism, higher cog-
nitive fluctuation, and visual hallucination scores com-
pared to the MCI-AD group.
EEG frequency analysis
The multivariate ANOVA revealed an overall effect of
diagnosis: F(10, 196) = 5.1, p < 0.001. Follow-up univari-
ate ANOVAs showed the following (see Table 2 and
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Figs. 2 and 3): There were no group differences in terms
of delta power. Theta power was increased in MCI-LB
(mean = 8.8, standard deviation (SD) = 4.8) compared to
controls (mean = 5.7, SD = 3.2) with no significant differ-
ence between controls and MCI-AD (mean = 7.0, SD =
3.1) or between the two MCI groups. Pre-alpha power
was increased in MCI-LB (mean = 28.8, SD = 14.2) and
MCI-AD (mean = 19.6, SD = 10.2) compared to controls
(mean = 13.3, SD = 9.2), and it was further increased in
MCI-LB compared to MCI-AD. Alpha power was de-
creased in MCI-LB (mean = 28.3, SD = 14.7) compared
to controls (mean = 39.9, SD = 15.8) with no difference
between controls and MCI-AD (mean = 35.6, SD = 12.7)
or between the two MCI groups. However, when the
alpha band was split further into low-alpha (8–10 Hz)
and high-alpha (10–13 Hz), it became evident that high-
alpha power was significantly reduced in MCI-LB com-
pared to both controls (p < 0.001) and MCI-AD (p <
0.001) with no difference between MCI-AD and controls
(p = 1.0) while there were no group differences in terms
of low-alpha power (F(2, 102) = 1.7, p = 0.2). Beta power
was reduced in MCI-LB (mean = 18.9, SD = 11.0) com-
pared to both controls (mean = 26.7, SD = 10.3) and
MCI-AD (mean = 25.4, SD = 8.7), but not different be-
tween MCI-AD and controls.
The theta/alpha ratio was increased in MCI-LB
(mean = 0.51, SD = 0.21) compared to controls (mean =
0.34, SD = 0.17), but not significantly different between
MCI-AD (mean = 0.42, SD = 0.16) and controls or be-
tween the two MCI groups.
Dominant frequency was slower in MCI-LB (mean =
7.2, SD = 1.1) compared to both MCI-AD (mean = 8.0,
SD = 1.1) and controls (mean = 8.4, SD = 1.2), but there
was no significant difference between controls and MCI-
AD. These results did not change when calculating the
dominant frequency from the occipital electrodes instead
Table 1 Demographic and clinical variables, mean (standard deviation)
HC (N = 31) MCI-AD (N = 36) MCI-LB (N = 39) Group differences
Male to female 22:9 15:21 35:4 χ2 = 20.0, p < 0.001a
p(HC,MCI-AD) = 0.02
p(HC,MCI-LB) = 0.045
p(MCI-AD,MCI-LB) < 0.001
Age 73.7 (7.3) 76.1 (7.7) 74.7 (6.4) F(2, 103) = 1.0, p = 0.38b
AChEI – 7 (19%)e 18 (46%)f χ2 = 5.7, p = 0.02c
PD meds – 0e 4 (10%)f χ2 = 3.8, p = 0.052c
Years of education 14.7 (4.0)g 12.9 (3.4)h 12.1 (2.8) F(2, 100) = 5.1, p = 0.008c
p(HC,MCI-AD) = 0.12
p(HC,MCI-LB) = 0.006
p(MCI-AD,MCI-LB) = 0.87
ACE-R 92.7 (4.2) 82.4 (8.5) 83.8 (9.2) t73 = 0.7, p = 0.50
d
MMSE 28.5 (1.1) 26.9 (2.1) 26.6 (2.5) t73 = 0.7, p = 0.51
d
UPDRS III 5.5 (4.4) 15.1 (13.8) 23.3 (14.2) t73 = 2.5, p = 0.01
d
DCFS – 6.9 (1.9)i 8.5 (3.3)k t61 = 2.4, p = 0.02
d
CAF total – 1.4 (2.7)i 3.7 (4.2)k t61 = 2.5, p = 0.02
d
NPI total – 8.6 (9.3)i 16.4 (12.9)k t61 = 2.7, p = 0.01
d
NEVHI – 0.8 (1.5)e 2.7 (4.1) t71 = 2.6, p = 0.01
d
GDS 1.3 (1.8) 3.5 (2.5) 5.1 (4.1) F(2, 103) = 13.4, p < 0.001b
p(HC,MCI-AD) = 0.01
p(HC,MCI-LB) < 0.001
p(MCI-AD,MCI-LB) = 0.08
ACE-R Addenbrooke’s Cognitive Examination–Revised, AChEI number of patients taking acetylcholinesterase inhibitors, CAF total clinician assessment of fluctuation
total score, DCFS Dementia Cognitive Fluctuation Scale, GDS Geriatric Depression Scale, HC healthy controls, MCI-AD mild cognitive impairment with Alzheimer’s
disease, MCI-LB probable mild cognitive impairment with Lewy bodies, MMSE Mini-Mental State Examination, NEVHI North-East Visual Hallucinations Interview, NPI
Neuropsychiatric Inventory, PD meds number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms, UPDRS III Unified
Parkinson’s Disease Rating Scale III (motor subsection)
aChi-square test HC, MCI-AD, MCI-LB
bUnivariate ANOVA HC, MCI-AD, MCI-LB
cChi-square test MCI-AD, MCI-LB
dStudent’s t test MCI-AD, MCI-LB
eN = 34
fN = 38
gN = 29
hN = 35
iN = 27
kN = 36
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of using all electrodes. Dominant frequency variability
was not significantly different between the groups.
The results did not change when restricting the ana-
lysis to the 21 electrodes that are part of the 10-20 sys-
tem (see Supplementary Table S1).
The regional analysis showed very similar results
compared to the analysis where all electrodes were
combined (see Supplementary Table S2). The only
slight difference was that alpha power was signifi-
cantly reduced in MCI-LB compared to MCI-AD pa-
tients in posterior (p = 0.047) and lateral (p = 0.01)
regions whereas mean alpha power from all electrodes
was not significantly different between the two MCI
groups (p = 0.07).
ROC analysis for diagnostic discrimination
Area under the ROC curve (AUC) values, sensitivity,
and specificity for the different EEG measures for differ-
entiating between MCI-LB and MCI-AD are shown in
Table 3. Beta power and dominant frequency achieved
the highest AUC values of 0.71 and 0.70, respectively.
Specificity was high for some measures (up to 0.97 for
alpha power); however, sensitivity was generally much
lower.
Association with clinical symptoms
There was a significant reduction in alpha power in
MCI-LB patients with visual hallucinations (N = 9, mean
(SD) = 19.1 (6.4)) compared to those without visual
Table 2 Group comparison of quantitative EEG characteristics
HC MCI-AD MCI-LB Group comparison
Delta power 14.1 [11.3, 17.0] 14.1 [11.8, 16.3] 14.9 [12.7, 17.1] F(2, 102) = 0.8, p = 0.47
Theta power 5.7 [4.6, 6.9] 7.0 [6.0, 8.1] 8.8 [7.2, 10.3] F(2, 102) = 4.8, p = 0.01
p(HC,MCI-AD) = 0.19
p(HC,MCI-LB) = 0.004
p(MCI-AD,MCI-LB) = 0.46
Pre-alpha power 13.3 [9.9, 16.7] 19.6 [16.1, 23.1] 28.8 [24.2, 33.4] F(2, 102) = 16.0, p < 0.001
p(HC,MCI-AD) = 0.006
p(HC,MCI-LB) < 0.001
p(MCI-AD,MCI-LB) = 0.02
Alpha power 39.9 [34.1, 45.6] 33.6 [29.3, 37.9] 28.3 [23.6, 33.1] F(2, 102) = 5.5, p = 0.005
p(HC,MCI-AD) = 0.39
p(HC,MCI-LB) = 0.001
p(MCI-AD,MCI-LB) = 0.07
Beta power 26.7 [22.9, 30.4] 25.4 [22.4, 28.4] 18.9 [15.3, 22.5] F(2, 102) = 8.1, p = 0.001
p(HC,MCI-AD) = 1.0
p(HC,MCI-LB) < 0.001
p(MCI-AD,MCI-LB) = 0.001
Theta/alpha ratio 0.34 [0.27, 0.40] 0.42 [0.36, 0.47] 0.51 [0.44, 0.57] F(2, 102) = 7.5, p < 0.001
p(HC,MCI-AD) = 0.22
p(HC,MCI-LB) = 0.001
p(MCI-AD,MCI-LB) = 0.10
DF, all electrodes 8.4 [8.0, 8.9] 8.0 [7.6, 8.3] 7.2 [6.8, 7.6] F(2, 102) = 8.7, p < 0.001
p(HC,MCI-AD) = 0.29
p(HC,MCI-LB) < 0.001
p(MCI-AD,MCI-LB) = 0.01
DF, occipital electrodes 8.5 [8.1, 9.0] 8.0 [7.6, 8.3] 7.3 [6.9, 7.7] F(2, 102) = 8.7, p < 0.001
p(HC,MCI-AD) = 0.16
p(HC,MCI-LB) < 0.001
p(MCI-AD,MCI-LB) = 0.03
DFV, occipital electrodes 1.3 [0.9, 1.6] 1.4 [1.1, 1.7] 1.0 [0.8, 1.2] F(2, 102) = 3.6, p = 0.03
p(HC,MCI-AD) = 0.54
p(HC,MCI-LB) = 1.0
p(MCI-AD,MCI-LB) = 0.17
Mean [95% confidence interval] of different quantitative EEG characteristics. Group comparisons were performed using univariate ANOVAs followed by post hoc
tests, Bonferroni-corrected for multiple comparisons. Sex was included as a covariate
DF dominant frequency, DFV dominant frequency variability, HC healthy controls, MCI-AD mild cognitive impairment with Alzheimer’s disease, MCI-LB probable
mild cognitive impairment with Lewy bodies
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hallucinations (N = 30, mean (SD) = 31.1 (15.4); t37 = 2.5,
p = 0.02; Fig. 4a). Additionally, the theta/alpha ratio was
increased in patients with visual hallucinations (mean
(SD) = 0.61 (0.13)) compared to patients without visual
hallucinations (mean (SD) = 0.47 (0.22), t24 = 2.4, p =
0.02, Fig. 4b).
None of the EEG measures showed a significant differ-
ence between those MCI-LB patients with cognitive fluc-
tuations (N = 21) compared to those without cognitive
fluctuations (N = 18) or between MCI-LB patients taking
cholinesterase inhibitors (N = 18) compared to those pa-
tients not taking cholinesterase inhibitors (N = 20, all
p > 0.1). Similarly, EEG measures were not different be-
tween MCI-AD patients taking cholinesterase inhibitors
(N = 7) compared to those MCI-AD patients not taking
these medications (N = 27).
MCI-LB patients with more than two core symptoms/
abnormal biomarkers had significantly higher pre-alpha
power, lower alpha power, and a higher theta/alpha ratio
compared to MCI-LB patients with only two core symp-
toms or one core symptom and one abnormal biomarker
(Supplementary Table S3). Higher delta power, theta
power, pre-alpha power, and theta/alpha ratio correlated
with higher Lewy body symptom/biomarker count
whereas higher alpha power, beta power, and dominant
frequency correlated with lower Lewy body symptom/
biomarker count (Supplementary Table S3). There were
no significant differences in overall cognition (ACE-R
scores) between MCI-LB patients with more than two
core symptoms/abnormal biomarkers compared to pa-
tients with two symptoms, and the Lewy body symptom/
biomarker count was not significantly correlated with
the ACE-R score (see Supplementary Table S3).
More severe cognitive impairment (as measured by the
ACE-R) was correlated with higher pre-alpha power,
lower alpha power, and decreased dominant frequency
in the MCI-AD group (Supplementary Table S4). In the
MCI-LB group, more severe cognitive impairment corre-
lated with higher theta power, higher pre-alpha power,
lower alpha power, higher theta/alpha ratio, and de-
creased dominant frequency (Supplementary Table S4).
Discussion
In this study, we investigated the differences in quantita-
tive EEG measures between highly phenotyped patients
with MCI-AD and MCI-LB and in comparison with
similarly aged healthy controls. We showed that there
are significant differences between the two MCI groups
at the group level with more severe EEG abnormalities
in MCI-LB compared to MCI-AD and that these EEG
changes correlated with the burden of Lewy body fea-
tures, supporting their high specificity for Lewy body
disease. However, their diagnostic accuracy for differen-
tiating MCI-LB from MCI-AD is modest and not con-
sistent with previous studies [17].
Overall, the findings suggest a slowing of the EEG in
MCI-LB patients compared to healthy controls by a shift
in power from beta and alpha frequency bands towards
slower frequencies in the pre-alpha and theta range. This
was also reflected by a shift of the dominant frequency
towards slower frequencies. These findings are consist-
ent with the results from previous EEG studies at the de-
mentia stage which generally report an increase in slow-
wave activity and slowing of the dominant EEG rhythm
in DLB [10, 18–20]. A slowing of the dominant fre-
quency has also been reported in MCI-LB patients be-
fore [21].
We did not observe any group differences in dominant
frequency variability which has previously been found to
be increased in DLB patients compared to controls [12,
17, 19]. However, other studies have failed to replicate
these findings [10, 18, 22], and our results further indi-
cate that an increase in dominant frequency variability
may not be a reliable feature of Lewy body disease.
The only difference between MCI-AD patients and
healthy controls was an increase in pre-alpha power,
suggesting only a small degree of EEG slowing. This is
again consistent with previous reports at the dementia
stage which have generally found less severe EEG abnor-
malities in AD compared to DLB [10, 12, 19]. Addition-
ally, we found significantly increased pre-alpha power,
decreased beta power, and slower dominant frequency
in the MCI-LB compared to the MCI-AD group, which
indicates more severe EEG slowing in MCI-LB than in
MCI-AD patients and mirrors the findings in dementia
patients. Furthermore, we found more severe EEG ab-
normalities in MCI-LB patients with more core Lewy
body symptoms and/or abnormal biomarkers and a
higher symptom count correlated with more severe EEG
slowing. This indicates that there is an association
Fig. 2 Mean power spectra for the three diagnostic groups. Shaded
areas indicate standard errors. HC, healthy controls; MCI-AD, mild
cognitive impairment with Alzheimer’s disease; MCI-LB, probable
mild cognitive impairment with Lewy bodies
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between more widespread Lewy body disease and more
severe EEG abnormalities and suggests that Lewy body
disease might affect electro-cortical activity in a dose-
dependent manner.
While there were significant group-level differences in
EEG characteristics between the two MCI groups, it is
difficult to translate this, at present, into a measure for
use in early clinical diagnosis. Power in the beta fre-
quency range and dominant frequency had the highest
diagnostic accuracy; however, they only reached moder-
ate AUC values of around 0.7. The specificity for MCI-
LB was very high for certain EEG measures (up to 0.97
for alpha power with a cutoff of < 20.5) which suggests
that if a substantial shift of power towards slower fre-
quencies is observed, i.e., in the case of a very abnormal
EEG, a diagnosis of MCI-LB over MCI-AD becomes
highly likely. The relationship between EEG slowing and
Lewy body symptom count (see above) suggests that
these might be the MCI-LB patients with more wide-
spread Lewy body disease and these are easier to distin-
guish from MCI-AD patients based on their more severe
EEG slowing. However, sensitivity was generally much
lower, i.e., in the case of a more normal EEG, differenti-
ating between MCI-AD and MCI-LB is difficult and
many MCI-LB cases would be missed by applying these
measures for diagnostic purposes. These findings thus
show that early changes in quantitative EEG characteris-
tics are specific, but not sensitive to Lewy body disease
which is in alignment with the diagnostic performance
of other biomarkers such as FP-CIT and MIBG in early
Lewy body disease [8].
In a previous EEG study in MCI patients, Bonanni
et al. [17] found that all MCI patients who converted to
DLB within a 3-year follow-up period had an abnormal
EEG whereas 93% of MCI patients who developed AD
within the follow-up period had normal EEGs. The high
specificity of EEG abnormalities for MCI-LB in this re-
port is in line with our findings whereas the high sensi-
tivity stands in contrast to the findings of the present
study. However, the sample in this previous study was
more selective by only including patients who developed
dementia within 3 years and might therefore be biased
towards MCI patients with more severe disease and thus
having a rapid progression to dementia. When also tak-
ing into account those MCI patients who did not con-
vert to dementia within 3 years, diagnostic accuracy was
reduced to an overall predictive value of 76% [17]. Fur-
thermore, in a multi-center study in dementia patients,
the diagnostic accuracy of EEG was also found to be
much lower [19], indicating that heterogeneity in EEG
acquisition and analysis protocols across different cen-
ters might be an important limiting factor.
Another previous EEG study that attempted to differ-
entiate MCI-AD from MCI-LB did not find any EEG
measures that reliably distinguished between the two
MCI subgroups [21]. However, this was a retrospective
study of selected MCI-AD and MCI-LB patients who
were recruited using clinical criteria which differed
across the several centers who supplied patient data.
Furthermore, participants from the different centers
were also assessed using different EEG protocols which
again makes the comparison difficult [21].
Table 3 Results from receiver operating characteristic (ROC) analysis to distinguish MCI-AD from MCI-LB
EEG measure AUC [95% CI] Cutoff for MCI-LB Sensitivity Specificity
Delta power 0.54 [0.41, 0.67] > 21.9 0.23 0.89
Theta power 0.60 [0.47, 0.73] > 10.7 0.33 0.89
Pre-alpha power 0.68 [0.56, 0.81] > 28.1 0.56 0.83
Alpha power 0.66 [0.53, 0.78] < 20.5 0.41 0.97
Beta power 0.71 [0.59, 0.83] < 19.0 0.61 0.81
Theta/alpha ratio 0.64 [0.51, 0.77] > 0.56 0.49 0.83
DF, all electrodes 0.70 [0.58, 0.82] < 7.1 0.51 0.86
DF, occipital electrodes 0.69 [0.57, 0.81] < 7.1 0.51 0.86
The sensitivity/specificity cutoff was determined using Youden’s index
AUC area under the receiver operating curve, CI confidence interval, DF dominant frequency, MCI-AD mild cognitive impairment with Alzheimer’s disease, MCI-LB
probable mild cognitive impairment with Lewy bodies
(See figure on previous page.)
Fig. 3 Group comparison of quantitative EEG characteristics. In each boxplot, the central line corresponds to the sample median; the upper and
lower border of the box represent the 25th and 75th percentile, respectively; and the length of the whiskers is 1.5 times the interquartile range.
Corresponding results from statistical comparisons between the groups are presented in Table 2. DF, dominant frequency; DFV, dominant
frequency variability; HC, healthy controls; MCI-AD, mild cognitive impairment with Alzheimer’s disease; MCI-LB, probable mild cognitive
impairment with Lewy bodies
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We explored the influence of the presence of visual
hallucinations on quantitative EEG characteristics in
MCI-LB patients and found that early EEG slowing, both
in terms of a reduction of power in the alpha frequency
range and a shift of power towards slower frequencies,
might be more severe in patients who experience visual
hallucinations compared to those patients who do not
have visual hallucinations, a finding which has previously
been reported in dementia patients [14]. However, the
number of patients experiencing visual hallucinations in
our cohort was small (N = 9) and these findings should
therefore be interpreted with caution, and replication in
a larger group of patients with a higher occurrence of
visual hallucinations is needed.
Limitations
Strengths of the present study include consistent and ro-
bust clinical assessments, diagnoses by a consensus
panel, the use of two diagnostic biomarkers, and the
prospective longitudinal design of the study. A potential
limitation is the use of acetylcholinesterase inhibitors in
the MCI patients as more patients in the MCI-LB group
were taking these medications compared to the MCI-AD
group. In the north east of England, services implement
expert advice and thus have high prescription rates for
DLB/MCI-LB patients because neuropsychiatric symp-
toms are treated using anti-dementia drugs early on. It
has been shown that cholinergic medication can
normalize EEG measures [15, 16], and it is therefore
possible that differences between the two MCI groups
were occluded by the higher number of MCI-LB patients
taking these medications. However, when comparing
MCI-LB patients who were taking acetylcholinesterase
inhibitors to those who were not, we did not find any
significant differences in any EEG measures. The same
was found in the MCI-AD patients although this result
should be interpreted with caution because of the small
number of MCI-AD patients who were taking acetyl-
cholinesterase inhibitors (N = 7). Furthermore, it would
be unethical to withdraw medication, and including
medicated patients is more reflective of clinical practice.
Another potential limitation is the lack of AD bio-
markers in our study.
Conclusions
In conclusion, the present study suggests that early
EEG slowing is specific to MCI-LB and, from a diagnos-
tic point of view, a very abnormal EEG favors MCI-LB
over MCI-AD. However, the overlap between the two
MCI groups is large, and for patients with a more nor-
mal EEG, it is difficult to distinguish between the two
MCI groups based on EEG characteristics alone. Given
its specificity for Lewy body disease burden, EEG may
be a promising future diagnostic biomarker and may
have value as part of a panel of other biomarkers. To
investigate this further, there needs to be a consensus
regarding the standardization of acquisition protocols,
analysis approaches, and choice of EEG parameters.
Work in this field will undoubtedly yield benefits simi-
lar to those seen with CSF biomarkers for example [23].
More complex EEG analyses such as functional con-
nectivity or source reconstruction methods may pro-
vide better sensitivity for detecting differences between
the two MCI groups as well as between MCI-AD pa-
tients and controls [21, 24]. Furthermore, multimodal
approaches including EEG features in addition to
MIBG/FP-CIT or structural MRI markers may be an-
other route by which it will be possible to achieve bet-
ter accuracy for the early distinction between AD and
DLB at the MCI stage.
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Fig. 4 Comparison of quantitative EEG characteristics between
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